AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
AbbVie (NYSE: ABBV) today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for...
